BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
24.95 EUR
-0.35 (-1.38%)
We assign a fundamental rating of 4 out of 10 to BLC. BLC was compared to 27 industry peers in the Health Care Providers & Services industry. BLC has only an average score on both its financial health and profitability. BLC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
BLC had positive earnings in 4 of the past 5 years.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BLC (0.08%) is worse than 78.13% of its industry peers.
BLC has a Return On Equity of 0.73%. This is in the lower half of the industry: BLC underperforms 71.88% of its industry peers.
BLC has a better Return On Invested Capital (6.40%) than 62.50% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.90%.
The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.40%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROIC | 6.4% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
BLC has a Profit Margin of 0.11%. This is in the lower half of the industry: BLC underperforms 78.13% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
The Operating Margin of BLC (8.17%) is better than 62.50% of its industry peers.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
With a decent Gross Margin value of 67.80%, BLC is doing good in the industry, outperforming 75.00% of the companies in the same industry.
BLC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
The number of shares outstanding for BLC remains at a similar level compared to 1 year ago.
The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
Compared to 1 year ago, BLC has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.40, we must say that BLC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BLC (1.40) is comparable to the rest of the industry.
BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
BLC has a Debt to FCF ratio (12.90) which is in line with its industry peers.
A Debt/Equity ratio of 5.29 is on the high side and indicates that BLC has dependencies on debt financing.
With a Debt to Equity ratio value of 5.29, BLC is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.4 |
ROIC/WACC1.27
WACC5.04%
2.3 Liquidity
A Current Ratio of 1.38 indicates that BLC should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.38, BLC is doing good in the industry, outperforming 68.75% of the companies in the same industry.
BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BLC (1.18) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
The earnings per share for BLC have been decreasing by -46.37% on average. This is quite bad
The Revenue has been growing slightly by 6.35% in the past year.
The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.96% yearly.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BLC is valuated quite expensively with a Price/Earnings ratio of 356.43.
Based on the Price/Earnings ratio, BLC is valued a bit more expensive than 78.13% of the companies in the same industry.
BLC is valuated expensively when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 9.13, the valuation of BLC can be described as very reasonable.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 93.75% of the companies in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 356.43 | ||
| Fwd PE | 9.13 |
4.2 Price Multiples
90.63% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 84.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.77 | ||
| EV/EBITDA | 5.65 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLC's earnings are expected to grow with 15.96% in the coming years.
PEG (NY)8.56
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3Y15.96%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (11/21/2025, 7:00:00 PM)
24.95
-0.35 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap183.88M
Revenue(TTM)491.18M
Net Income(TTM)528.00K
Analysts83.33
Price Target36.72 (47.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.84%
EPS NY rev (3m)-8.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 356.43 | ||
| Fwd PE | 9.13 | ||
| P/S | 0.37 | ||
| P/FCF | 5.77 | ||
| P/OCF | 2 | ||
| P/B | 2.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.65 |
EPS(TTM)0.07
EY0.28%
EPS(NY)2.73
Fwd EY10.95%
FCF(TTM)4.32
FCFY17.33%
OCF(TTM)12.48
OCFY50.01%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)8.56
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROCE | 8.71% | ||
| ROIC | 6.4% | ||
| ROICexc | 6.78% | ||
| ROICexgc | 12.12% | ||
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.25% | ||
| Profit Quality | 6036.93% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.4 |
F-Score8
WACC5.04%
ROIC/WACC1.27
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
EBIT growth 1Y18.25%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3Y39.49%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 356.43 and the Price/Book (PB) ratio is 2.55.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.77%.